Cell therapy

An international team of scientists has shown that a stem cell therapy for multiple sclerosis (MS) could prevent further damage to the brain. The early-stage clinical trial was the result of a collaboration between researchers at University of Colorado Anschutz Campus, the University of Cambridge and the University of Milano-Bicocca. “We don’t know yet whether […]

Hailed as a revolution in the treatment of many diseases, cell and gene therapy is the fastest growing area of therapeutics. This eBook, ‘Cell & Gene Therapy: The advances and innovation’, provides a comprehensive overview of the latest innovations in cell and gene therapies, where the challenges lie and the possible solutions to overcoming these […]

This 24-page eBook sponsored by Sartorius explores the latest innovations in cell and gene therapies, where the challenges lie and the possible solutions to overcoming these obstacles. Download this free resource to learn more about: The ways cell and gene therapies (CGTs) are revolutionising medicine in a range of diseases How to navigate diverging regulatory expectations […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The breaking news this week was certainly the first regulatory approval for Casgevy, not only the first gene therapy approved for sickle cell […]

News round-up for 13-17 November by DDW Digital Content Editor Diana Spencer. The breaking news this week was certainly the first regulatory approval for Casgevy, not only the first gene therapy approved for sickle cell disease, but also the first therapy to use CRISPR gene editing. However, there were a number of other breakthroughs announced […]

Arcellx has revealed encouraging interim data from its Phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The company plans to present new data with a median follow-up of 26.5 months at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place 9-12 December 2023 in San Diego, […]

New trial evidence has shown that Kite’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel: axi-cel) reduces the risk of death by 27.4% in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), corresponding to a 38% improvement in overall survival (OS). It is the only treatment in nearly 30 years to show statistically significant OS, […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, […]

News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer. My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases. The top stories: Natural killer cell therapy shows […]

Download the ‘Advanced Flow Cytometry Handbook‘ to discover the easier way to do flow cytometry. In this new handbook, Sartorius introduces the value of advanced flow cytometry, to ensure that every scientist feels empowered to run an experiment and analyse the data with confidence. This easy-to-use digital guide includes an introduction to the iQue Advanced […]

Are you missing out on the easier way to do flow cytometry? In this new handbook, Sartorius introduces the value of advanced flow cytometry, so every scientist feels empowered to run an experiment and analyse the data with confidence. This easy-to-use digital guide includes an introduction to the iQue® Advanced Flow Cytometry Platform and multiplexed […]

Gamida Cell has revealed early data in 10 patients with CD20 positive non-Hodgkin lymphoma as part of an ongoing study of natural killer (NK) cell therapy candidate GDA-201. The multicentre Phase I study is designed to evaluate safety and determine the maximum tolerated dose. Enrolled patients were heavily pretreated with a median of six prior […]

Both GTPs and GMPs must be followed to get cell-based advanced therapies or tissue-based therapy products to market. Learn about important considerations when sourcing Leukocytes/Cellular starting materials and related ancillary products that must be factored into your programme to efficiently move through the clinical pipeline and successfully receive regulatory approval. In this webinar from BioIVT, the […]

Advanced Therapies Europe took place from 9-12 September 2023 in Portugal. DDW’s Megan Thomas asked attendees: What is most important to scale from discovery to commercialisation of cell and gene therapies (CGTs)? Joel Eichmann, Co-Founder, Green Elephant Biotech It always comes down to time-to-market and risk minimisation. To cover these, it is critical to choose […]

A new Whitepaper is available from Thermo Fisher Scientific, entitled ‘Lentiviral vector characterization for cell and gene therapy manufacturing using the QuantStudio Absolute Q Digital PCR System’. Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as […]

Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as digital PCR to characterise lentiviral vectors and the cells transduced with them are critical to helping ensure the safety and efficacy of these biologics. Download this new […]